An EvoNexus Incubator Company
LynxBiosciences(LynxBio)is a cytomics company focused on transforming the development of blood cancer therapies and delivering precise patient management by identifying the most promising therapeutic options.
Many blood cancers are incurable; the standard of care is empirical treatment, typically through a trial and error process. Our initial focus is multiplemyeloma (MM) whereas patients ultimately relapse and undergo on average 5-7 treatments (ranging from $125,000 to $450,000 p.a.)
LynxBio is addressing a growing unmet need in the blood cancer space by providing an efficient and accurate platform to rapidly identify the clinical treatment response of a patient to multiple drugs exvivo,allowing physicians and providers to choose the most promising treatment option.